Gilead upped on HIV franchise; Merck downgraded on Keytruda LoE at Deutsche Bank
Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, ...
Deutsche downgrades Merck ahead of Keytruda 2028 expiration
Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...
Becker's Hospital Review15d
Keytruda's looming patent expiry raises concerns: 5 notes
The company's stock recently dropped 9% following a disappointing update on the vaccine business in China, further emphasizing the risks of overdependence on one blockbuster drug. Keytruda ...
Merck Stock Falls After Rival Summit Beats Keytruda Cancer Drug in Trial
Merck stock fell early Monday after a rival pharmaceutical company said its cancer drug beat Merck’s Keytruda in a ...
Barron's8mon
Competitor to Merck's Keytruda Worries Some Investors
Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab ...
Seeking Alpha27d
Merck, Eisai post mixed Phase 3 data for Keytruda/ Lenvima in GIT cancer
Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Ja ...